Free Trial
NASDAQ:NXL

Nexalin Technology 3/14/2025 Earnings Report

Nexalin Technology logo
$0.96 +0.03 (+2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$0.96 0.00 (-0.21%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nexalin Technology EPS Results

Actual EPS
-$0.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nexalin Technology's next earnings date is estimated for Friday, November 14, 2025, based on past reporting schedules.

Conference Call Resources

Nexalin Technology Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions.

Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.

View Nexalin Technology Profile

More Earnings Resources from MarketBeat